Algert Global LLC Acquires 22,010 Shares of Encompass Health Corporation $EHC

Algert Global LLC increased its holdings in shares of Encompass Health Corporation (NYSE:EHC) by 53.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,985 shares of the company’s stock after purchasing an additional 22,010 shares during the period. Algert Global LLC owned approximately 0.06% of Encompass Health worth $8,000,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in EHC. Citizens National Bank Trust Department bought a new position in Encompass Health during the third quarter worth $26,000. First Horizon Corp bought a new stake in Encompass Health in the third quarter valued at $34,000. Westside Investment Management Inc. raised its holdings in shares of Encompass Health by 56.7% during the third quarter. Westside Investment Management Inc. now owns 279 shares of the company’s stock valued at $35,000 after purchasing an additional 101 shares during the period. Assetmark Inc. raised its holdings in shares of Encompass Health by 88.1% during the third quarter. Assetmark Inc. now owns 299 shares of the company’s stock valued at $38,000 after purchasing an additional 140 shares during the period. Finally, Root Financial Partners LLC bought a new position in shares of Encompass Health during the 3rd quarter worth about $39,000. 97.25% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, Treasurer Edmund Fay sold 11,937 shares of Encompass Health stock in a transaction on Monday, March 9th. The shares were sold at an average price of $107.00, for a total transaction of $1,277,259.00. Following the transaction, the treasurer directly owned 89,325 shares of the company’s stock, valued at $9,557,775. The trade was a 11.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mark J. Tarr sold 150,000 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $111.64, for a total transaction of $16,746,000.00. Following the completion of the sale, the chief executive officer owned 377,070 shares of the company’s stock, valued at approximately $42,096,094.80. The trade was a 28.46% decrease in their position. The SEC filing for this sale provides additional information. 2.10% of the stock is currently owned by company insiders.

Encompass Health Price Performance

EHC stock opened at $101.48 on Tuesday. The company has a market capitalization of $10.09 billion, a P/E ratio of 18.32, a price-to-earnings-growth ratio of 1.92 and a beta of 0.70. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 1.08. Encompass Health Corporation has a 52-week low of $92.77 and a 52-week high of $127.99. The business has a 50-day simple moving average of $103.45 and a two-hundred day simple moving average of $112.75.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Thursday, February 5th. The company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.17. Encompass Health had a return on equity of 18.20% and a net margin of 9.54%.The firm had revenue of $3.09 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same period in the previous year, the company posted $1.17 EPS. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. Research analysts expect that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Wednesday, April 1st will be given a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, April 1st. Encompass Health’s dividend payout ratio is presently 13.72%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Barclays boosted their target price on Encompass Health from $150.00 to $153.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Zacks Research cut Encompass Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 19th. Finally, Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a report on Sunday, January 18th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Encompass Health currently has an average rating of “Buy” and an average target price of $143.29.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.